(4-甲氧基苯基)N-甲基氨基甲酸酯 | 3938-29-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (4-甲氧基苯基)N-甲基氨基甲酸酯
• 英文名称: 4-methoxyphenyl N-methylcarbamate
• 英文别名: p-Methoxyphenylmethylcarbamat；p-Methoxyphenyl-N-methylcarbamat；N-Methyl-O-(p-methoxyphenyl)-carbamat；4-Anisylmethylcarbamat；N-methyl-carbamic acid 4-methoxy-phenyl ester；4-Methoxyphenyl-N-methylcarbamat；4-Methoxyphenylmethylcarbamat；4-Anisyl-N-methylcarbamat；Phenol, 4-methoxy-, methylcarbamate；(4-methoxyphenyl) N-methylcarbamate
• CAS: 3938-29-2
• 化学式: C₉H₁₁NO₃
• 分子量: 181.191
• InChiKey: PFPSRAGMOKCNIC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  47.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  聚合甲醛 、 (4-甲氧基苯基)N-甲基氨基甲酸酯 、 sodium 4-nitrobenzenesulfinate 以 甲酸 为溶剂， 生成 Methyl-(4-nitro-benzenesulfonylmethyl)-carbamic acid 4-methoxy-phenyl ester
  参考文献：
  名称：

  van Est-Stammer,R.; Engerts,J.B.F.N., Recueil des Travaux Chimiques des Pays-Bas, 1971, vol. 90, p. 1307 - 1319

  摘要：

  DOI：
• 作为产物：
  描述：

  甲基甲基氨基甲酸酯 以40%的产率得到
  参考文献：
  名称：

  Deshpande Sunita R., Likhite Anjali P., Rajappa Srinivasachari, Tetrahedron, 50 (1994) N 34, S 10367-10370

  摘要：

  DOI：

文献信息

• Amide derivatives and their use as inhibitors of 11-beta-hydroxysteroid dehydrogenase type I
  申请人：Coppola Mark Gary

  公开号：US20060205772A1

  公开（公告）日：2006-09-14

  Compounds of the formula (I) provide pharmacological agents which lower intracellular glucocorticoid concentrations in mammals, in particular, intracellular cortisol levels in humans. Therefore, the compounds of the instant invention improve insulin sensitivity in the muscle and the adipose tissue, and reduce lipolysis and free fatty acid production in the adipose tissue. The compounds of the invention lower hepatic glucocorticoid concentration in mammals, in particular, hepatic cortisol concentration in humans, resulting in inhibition of hepatic gluconeogenesis and lowering of plasma glucose levels. Thus, the compounds of the instant invention may be particularly useful in mammals as hypoglycemic agents for the treatment and prevention of conditions in which hyperglycemia and/or insulin resistance are implicated, such as type-2 diabetes. The compounds of the invention may also be used to treat other glucocorticoid associated disorders, such as Syndrome-X, dyslipidemia, hypertension and central obesity. The invention furthermore relates to the use of the compounds according to the invention for the preparation of medicaments, in particular of medicaments useful for the treatment and prevention of glucocorticoid associated disorders, by improving insulin sensitivity, reducing plasma glucose levels, reducing lipolysis and free fatty acid production, and by decreasing

  化合物(I)的配方提供了降低哺乳动物细胞内糖皮质激素浓度的药物，特别是降低人类细胞内皮质醇水平的药物。因此，本发明的化合物改善了肌肉和脂肪组织中的胰岛素敏感性，并减少了脂肪组织中的脂解和游离脂肪酸产生。本发明的化合物降低了哺乳动物肝脏中的糖皮质激素浓度，特别是人类肝脏中的皮质醇浓度，从而抑制了肝糖异生并降低了血浆葡萄糖水平。因此，本发明的化合物在哺乳动物中可能特别有用作为降糖药物，用于治疗和预防与高血糖和/或胰岛素抵抗有关的疾病，例如2型糖尿病。本发明的化合物还可用于治疗其他与糖皮质激素相关的疾病，例如综合征X、血脂异常、高血压和中心性肥胖。此外，本发明还涉及使用根据本发明的化合物制备药物，特别是用于改善胰岛素敏感性、降低血浆葡萄糖水平、减少脂解和游离脂肪酸产生，并通过降低糖皮质激素浓度来降低肝糖异生的药物，用于治疗和预防糖皮质激素相关疾病。
• Novel Tetracyclic Tetrahydrofuran Derivatives Containing Cyclic Amine Side Chain
  申请人：Cid-Nunez Jose Maria

  公开号：US20080262076A1

  公开（公告）日：2008-10-23

  This invention concerns novel substituted tetracyclic tetrahydrofuran derivatives containing a cyclic amine side chain with binding affinities towards dopamine receptors, in particular dopamine D 2 receptors, towards serotonin receptors, in particular 5-HT 2A and 5-HT 2C receptors, and pharmaceutical compositions comprising the compounds according to the invention, the use thereof as a medicine, in particular for the prevention and/or treatment of a range of psychiatric and neurological disorders, in particular certain psychotic, cardiovascular and gastrokinetic disorders and processes for their production. The compounds according to the invention can be represented by general Formula (I) and comprises also a pharmaceutically acceptable acid or base addition salt thereof, an N-oxide form thereof or a quaternary ammonium salt thereof, wherein all substituents are defined as in Claim 1.

  本发明涉及一种新型取代四环四氢呋喃衍生物，其含有一个环状胺侧链，具有结合多巴胺受体的亲和力，特别是多巴胺D2受体，对5-HT2A和5-HT2C受体的亲和力，以及包含根据本发明的化合物的制药组合物，其用作药物，特别是用于预防和/或治疗一系列精神和神经疾病，特别是某些精神病、心血管和胃动力紊乱，并提供其生产过程。根据本发明的化合物可以用一般式（I）表示，并包括其药学上可接受的酸或碱盐、N-氧化物形式或季铵盐，其中所有取代基在权利要求书1中定义。
• POLYMER CONJUGATES OF GLP-1
  申请人：BOSSARD Mary J.

  公开号：US20130096258A1

  公开（公告）日：2013-04-18

  Conjugates of a GLP-1 moiety may be covalently attached to one or more water-soluble polymers. For instance, a GLP-1 polymer conjugate may include a GLP-1 moiety releasably attached at its N-terminus to a water-soluble polymer. The GLP-1 polymer conjugate may include a GLP-1 moiety covalently attached to a water-soluble polymer, wherein the GLP-1 moiety possesses an N-methyl substituent.

  GLP-1分子的共轭物可以共价地附着在一个或多个水溶性聚合物上。例如，GLP-1聚合物共轭物可以包括一个GLP-1分子，在其N-末端可释放地附着在水溶性聚合物上。GLP-1聚合物共轭物可以包括一个GLP-1分子共价地附着在水溶性聚合物上，其中GLP-1分子具有一个N-甲基取代基。
• NOVEL VINBLASTINE DERIVATIVES, THEIR PREPARATION, USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAID DERIVATIVES
  申请人：Shanghai Institute of Materia Medica, Chinese Academy of Sciences

  公开号：EP2119720A1

  公开（公告）日：2009-11-18

  The invention provides vinblastine derivatives represented by the following formula 1 or their physiologically acceptable salts, their preparation, use and pharmaceutical compositions comprising the said derivatives. The said vinblastine derivatives show inhibiting activities against tumor cell lines and can be used as medicaments for treating malignant tumors.

  本发明提供了由下式 1 表示的长春新碱衍生物或其生理上可接受的盐、其制备方法、用途以及包含上述衍生物的药物组合物。上述长春新碱衍生物对肿瘤细胞株具有抑制活性，可用作治疗恶性肿瘤的药物。
• Elimination-addition mechanisms of acyl group transfer: the hydrolysis and synthesis of carbamates
  作者：Huda Al-Rawi、Andrew Williams

  DOI：10.1021/ja00450a045

  日期：1977.4

表征谱图